Alamar Biosciences, a precision proteomics company focused on early disease detection, has launched its NULISAqpcr™ AD 5‑Plex Assay for research use.
The assay allows simultaneous measurement of five key blood-based biomarkers linked to Alzheimer’s disease: BD-pTau217, amyloid-beta 42 (Aβ42), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and APOE4 carrier status—all from a single blood or plasma sample.
By consolidating multiple biomarkers into a single multiplexed format, the assay provides enhanced sensitivity and specificity, enabling robust monitoring of amyloid and tau pathology, neurodegeneration, inflammation, and genetic risk. Its applications extend beyond Alzheimer’s disease to other neurodegenerative and cognitive disorders, supporting translational and clinical research.
The NULISAqpcr AD 5‑Plex Assay is now available as a service through Alamar’s Technology Access Program, offering researchers and clinicians a streamlined tool for early detection, precision diagnostics, and biomarker-driven studies in neurodegenerative disease.
